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Abstract
Background: Macrophage polarization programs, commonly referred to as “classical” and “alternative” activation, are
widely considered as distinct states that are exclusive of one another and are associated with different functions such
as inflammation and wound healing, respectively. In a number of disease contexts, such as traumatic brain injury (TBI),
macrophage polarization influences the extent of pathogenesis, and efforts are underway to eliminate pathogenic
subsets. However, previous studies have not distinguished whether the simultaneous presence of both classical and
alternative activation signatures represents the admixture of differentially polarized macrophages or if they have
adopted a unique state characterized by components of both classical and alternative activation.
Methods: We analyzed the gene expression profiles of individual monocyte-derived brain macrophages responding to
TBI using single-cell RNA sequencing. RNA flow cytometry was used as another single-cell analysis technique to validate
the single-cell RNA sequencing results.
Results: The analysis of signature polarization genes by single-cell RNA sequencing revealed the presence of diverse
activation states, including M(IL4), M(IL10), and M(LPS, IFNγ). However, the expression of a given polarization marker was
no more likely than at random to predict simultaneous expression or repression of markers of another polarization
program within the same cell, suggesting a lack of exclusivity in macrophage polarization states in vivo in TBI. Also
unexpectedly, individual TBI macrophages simultaneously expressed high levels of signature polarization genes across
two or three different polarization states and in several distinct and seemingly incompatible combinations.
Conclusions: Single-cell gene expression profiling demonstrated that monocytic macrophages in TBI are not comprised
of distinctly polarized subsets but are uniquely and broadly activated. TBI macrophage activation in vivo is deeply
complex, with individual cells concurrently adopting both inflammatory and reparative features with a lack of
exclusivity. These data provide physiologically relevant evidence that the early macrophage response to TBI is comprised
of novel activation states that are discordant with the current paradigm of macrophage polarization—a key consideration
for therapeutic modulation.
Keywords: Innate immunity, Macrophage, Monocyte, Traumatic brain injury, Single-cell RNA sequencing,
Neuroinflammation, RNA flow cytometry, Polarization, Neurotrauma, Myeloid cells
* Correspondence: Christine.hsieh@ucsf.edu
Mary C. Nakamura and Christine L. Hsieh are co-authors.
3Department of Medicine, Division of Rheumatology, University of California,
San Francisco, 4150 Clement St. 111R, San Francisco, CA 94121, USA
4Research Department, Immunology Section, San Francisco VA Medical
Center, 4150 Clement St. 111R, San Francisco, CA 94121, USA
Full list of author information is available at the end of the article
© 2016 Kim et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Journal of Neuroinflammation  (2016) 13:117 
DOI 10.1186/s12974-016-0581-z
Background
Immune responses are heterogeneous and comprised of
a combination of antimicrobial, tissue reparative, and
regulatory functions. In certain contexts, some of these
processes are pathogenic; in particular, inflammation is
associated with worse outcomes in diseases ranging from
cardiovascular disease to neurodegeneration. In traumatic
brain injury (TBI), which accounts for 30 % of deaths re-
lated to injury [1, 2] and impacts an estimated 2 % of the
US population who live with persistent disabilities result-
ing from TBI [1–3], neuroinflammation has been recog-
nized as a pathogenic factor and has garnered significant
attention as a potential target for therapy [1, 3–5].
Neuroinflammation develops within hours after TBI
and can persist for months to years. Delivering early inter-
ventions during the first hours to days following injury
may be critical for restraining lesion expansion [1, 2].
However, therapeutic amelioration of neuroinflammation
is complicated by the fact that it is dynamic, multifaceted,
and also critical for wound repair [1, 3, 6–8]. For example,
it was shown that inhibition of CCR2 during TBI can limit
lesion size; however, the same receptor is also responsible
for the protection from tau pathologies [9]. As such,
identification of the precise molecular pathways and
cellular subsets that impact pathology and/or cognitive
recovery following TBI could lead to therapies that dir-
ectly antagonize harmful mechanisms while preserving,
or even enriching, beneficial mechanisms.
Monocyte-derived macrophages (hereafter referred to as
“macrophages”) are early responders to infection and tissue
injury. Macrophages can be activated to express a variety of
divergent functional programs—a process known as
“polarization” [10, 11]. Both in vitro and in vivo studies
demonstrate that with specific stimuli, human and mouse
macrophages can polarize towards functionally divergent
subsets, each possessing a distinct phenotype and gene ex-
pression profile [10–13]. Macrophage polarization and its
importance for health are established in host defense, me-
tabolism, and thermogenesis, and for pathology in obesity,
cancer, allergy, and atherosclerosis [13–15]. Historically,
macrophages have been classified as classical (M1) macro-
phages, which promote inflammation, or as alternatively ac-
tivated (M2) macrophages, which restrict inflammation and
foster wound repair. The M1/M2 concept has evolved to
better account for the complexity of states; as such, it has
been suggested that the polarization state of activated mac-
rophages be designated by the prototypical stimulus that
can produce the state in vitro—specifically, the proposed
classes include M(lipopolysaccharide (LPS), interferon-γ
(IFNγ)), M(IL4), M(immunocomplex (Ic)), M(IL10), and
M(glucocorticoid (GC), transforming growth factor-β
(TGFβ)) [11]. However, in contrast to the in vitro-derived
classifications of macrophage programs, in vivo and com-
binatorial stimulation studies suggest that macrophages can
differentiate along a spectrum of phenotypes and also
exhibit plasticity in shifting from one phenotype to another
[10, 11, 16]. Thus, although the definition of in vitro
polarization states continues to advance, our understanding
of in vivo polarization remains understudied.
Studies of macrophage polarization following TBI, in-
cluding one of our own, suggest that macrophages ex-
hibit heterogeneous expression of both inflammatory
M1 and wound healing M2 markers [6–8, 17, 18]. To
date, studies of macrophage activation following TBI
have averaged the response by whole tissue or by bulk
populations of leukocytes or macrophages. It is therefore
unclear whether co-expression of M1 and M2 markers
represents an admixture of differentially polarized mac-
rophages (in the cases of whole tissue or bulk leukocyte
analysis, gene expression could also be an average of
microglia, macrophages, neutrophils, and other cells) or
a more homogeneous, but uniquely polarized, state of
macrophages. To distinguish between the above possibil-
ities, we used RNA sequencing (RNAseq) [19] and RNA
flow cytometry to analyze the polarization state of indi-
vidual ipsilateral monocyte-derived brain macrophages
1 day after experimental injury. The 1-day time point
was selected to understand early macrophage activation
states at a time at which an immunomodulatory inter-
vention could be delivered to minimize and/or alter the
ensuing inflammatory response and associated damage.
Within the TBI macrophage population, we detected
gene expression signatures of M(IL4), M(LPS, IFNγ),
and M(IL10) polarization; however, within individual
TBI macrophages, expression of signature markers, even
the highest expression of signature genes, from distinct
classes commonly co-occurred within the same cell.
Moreover, the expression of a given class marker was no
more likely than at random to predict expression or re-
pression of markers of another class, suggesting a lack of
exclusivity in macrophage activation states. Our findings
highlight the complex nature of macrophage polarization
in vivo and the utility of high dimensionality, single-cell
assays for its interrogation.
Methods
Animals
Twelve- to sixteen-week-old male C57BL/6 cage mate
mice (Jackson Laboratories, Sacramento, CA) were
housed at the San Francisco VA Medical Center. Con-
trolled cortical impact (CCI) or sham surgery was
performed as approved by the VA Animal Care Commit-
tee. Animals were anesthetized with 3 % isoflurane with
oxygen and were administered bupivacaine s.c. above
the skull. The scalp was incised. A 2-mm circular cra-
niectomy with center coordinates of 1.5 mm lateral and
2.3 mm posterior to the bregma point was performed.
Care was taken to not breach the dura by not drilling
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completely through the skull. No animals in this study
showed signs of excessive bleeding or dural breach
from the craniectomy procedure. TBI was induced by a
sterile, pneumatic, circular, flat-tipped piston with im-
pact parameters of 3 m/s velocity, 150 ms dwell time,
and 1.5 mm depth (Amscien Instruments, Richmond,
VA, with extensive modifications by H&R Machine,
Capay, CA). These CCI parameters led to bleeding, and
pressure was gently applied with a cotton swab until
bleeding had halted, and the skin was stapled shut.
Sham-injured mice received surgical procedures with-
out piston impact.
Brain leukocyte isolation
Ipsilateral brain hemispheres were harvested 1 day
post-surgery following whole-body perfusion to elimin-
ate circulating blood. Tissues were pooled, mechanic-
ally dissociated into suspension, and washed in GKN
buffer (8 g/L NaCl, 0.4 g/L KCl, 1.41 g/L Na2HPO4,
0.6 g/L NaH2PO4, and 2 g/L D(+) glucose, pH 7.4).
Cells were resuspended in NOSE buffer (4 g/L MgCl2,
2.55 g/L CaCl2, 3.73 g/L KCl, 8.95 g/L NaCl, pH 6–7)
supplemented with 200 U/ml DNase I (Sigma-Aldrich,
St. Louis, MO) and 0.2 mg/ml collagenase type I
(Worthington Biochemical, Lakewood, NJ) and incu-
bated at 37 °C for 30 min. Washed cells were separated
on a discontinuous isotonic Percoll gradient (90 %
Percoll, 10 % 1.5 M NaCl, GE Biosciences, Pittsburgh,
PA) by suspending cells in 20 mL of a 1.03 g/ml Percoll
solution in GKN buffer and underlaying the cells with
10 ml of 1.095 g/L Percoll in PBS. Cells were centri-
fuged at 900×g for 20 min without brake. The buffy
layer was isolated for further study.
Bone marrow-derived macrophages
Mice were sacrificed by inhaled isoflurane sedation
followed by cervical dislocation. Femurs were harvested,
bone ends were snipped, and the bones were flushed
with PBS. Marrow was resuspended and spun into a pellet.
Cells were resuspended into 2 ml of red blood cell lysis
buffer for 2 min and washed with PBS. Cells were plated
into two 10-cm non-TC-coated petri dishes per femur.
Bone marrow cells were cultured in RPMI or alpha-MEM
(Thermo Fisher Scientific, Waltham, MA) supplemented
with 10 % FCS, 1 % penicillin-streptomycin, and 10 %
CMG for 8 days. Bone marrow-derived macrophages
(BMDM) were polarized with 20 ng/ml IL-4 (Peprotech,
Rocky Hill, NJ) for 18 h or 100 μg/ml LPS from Salmon-
ella enterica (Sigma-Aldrich) for 2–3 h.
Single-cell RNA sequencing
Ipsilateral TBI brain hemispheres were pooled from
three age-matched male cage mate mice and brain leu-
kocytes were isolated as described above. TBI brain
macrophages were sorted to 99.8 % purity on a FAC-
SAria IIu (BD Biosciences, San Jose, CA) located at the
San Francisco General Hospital. The following antibodies
from eBioscience (San Diego, CA) were used: CD45 (clone
30-F11), Ly6G (clone 1A8), F4/80 (clone BM8), and
CD11b (clone M1/70). Sytox blue (Thermo Fisher Scien-
tific) was used at a final concentration of 1 μm. Follow-
ing cell sorting, single cells were immediately loaded
onto a Fluidigm C1 chip (Fluidigm Corporation, South
San Francisco, CA) and prepared into RNAseq librar-
ies following manufacturer protocols. Nextera XT
(Illumina, San Diego, CA) DNA library generation re-
agents were used to fragment and barcode libraries.
Single-cell DNA libraries were sequenced as 51 bp
reads on an Illumina HiSeq 2500 running in high out-
put mode by the UCSF Center for Advanced Technol-
ogy. Reads were aligned to the GRCm38 release of the
mouse genome using RSEM with default parameters.
Gene expression was reported as transcripts per million
(TPM). Quality analysis was performed using custom
scripts and FASTQC (http://www.bioinformatics.babraha-
m.ac.uk/projects/fastqc/). Samples with fewer than one
million aligned reads or with fewer than 50 % of reads
mapped were excluded.
RNA flow cytometry
Intracellular RNA flow cytometry was performed using
PrimeFlow RNA (Affymetrix, Santa Clara, CA) reagents
following manufacturer’s protocols. Cell viability was
assessed by Fixable Viability dyes eFluor 506 or eFluor
455UV (eBioscience). Cell surface markers were stained
using antibodies against CD45 (clone 30-F11), CD11b
(clone M1/70), Ly6G (clone 1A8), and Ly6C (clone
HK1.4). A DapB RNA probe, a probe for RNA of a bacter-
ial gene, served as a control for non-specific nucleic acid
binding that could occur in activated macrophages. The
following RNA probes were used: DapB, Arg1, Mrc1,
Chi3l3, Tnf, and Il1b. Cell staining was analyzed on a
FACSAria IIu located at the San Francisco VA Medical
Center or the San Francisco General Hospital. Data
analysis was performed by using FlowJoX (Treestar,
Ashland, OR). For BMDM, three independent RNA
flow cytometry experiments were performed. For TBI
mice, six separate RNA flow cytometry experiments
were performed, each with pooled ipsilateral hemi-
spheres from eight age-matched cage mates. For sham-
injured mice, three independent RNA flow cytometry
experiments were performed, with pooled ipsilateral
hemispheres from six to ten age-matched cage mates.
Statistical analysis
Prism 6.0 (Graphpad, San Diego, CA) software was
used to perform linear regression analyses and Mann-
Whitney U tests.
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Results
Validation of RNAseq profiles of single monocytes
responding to TBI
Our previous approach of bulk-profiling-purified brain
macrophages responding to experimental TBI demon-
strated that macrophages expressed a mixture of signature
polarization genes representing both classical and alterna-
tive activation [6]. It was unclear whether this mixed
polarization signature reflected (in a non-mutually exclu-
sive manner): (1) a mixture of classically and alternatively
activated macrophage subsets, (2) an intermediate
polarization state of macrophages that are transitioning
between states, or (3) unusual subsets of macrophages
adopting a stable state distinct from our current defini-
tions of polarization. We thus employed single-cell RNA
sequencing to profile the whole transcriptome at the reso-
lution of individual cells.
We purified individual macrophages isolated from the
ipsilateral hemisphere of mouse TBI brains 1 day post-
injury. Monocyte-derived macrophages of hematopoietic
origin were defined as CD45hi Ly6G− CD11b+ F4/80+
cells (Fig. 1a) [20], which we demonstrated are a popula-
tion of infiltrating macrophages that fail to increase in
Ccr2−/− mice 1 day after TBI [21]. Macrophages were
isolated to high purity (99.8 %) by two successive rounds
of flow cytometric sorting (Fig. 1a), and single purified
cells were isolated using a Fluidigm C1 and processed
into individual RNAseq libraries for transcriptome ana-
lysis. Libraries for 63 cells were prepared and sequenced;
average base quality across all samples was >Q36, and
reads exhibited other characteristics of high-quality se-
quence (Additional file 1: Figure S1). Upon alignment of
reads to the mouse genome, 45 cells exceeded our mini-
mum quality criteria.
To validate the lineage of our sorted cells, we assessed the
expression of 32 markers of both non-hematopoietically
and hematopoietically derived cells. Expression of the
lineage markers was consistent with high purity of the
isolated macrophages. Specifically, all cells expressed high
levels of myeloid markers, such as Fcgr1 (CD64) and
Cd68, and nearly every cell expressed adhesion G protein-
coupled receptor E1 (Adgre1; F4/80) and mer proto-
Fig. 1 Transcriptional profiles of lineage markers as determined by single-cell RNA sequencing of individual TBI macrophages. a Mouse leukocytes
were harvested from pooled ipsilateral hemispheres of brain tissue 1 day post-TBI and cell sorted for macrophages by flow cytometry. Flow cytometry
gates for cell sorting of live TBI macrophages (CD45hi Ly6G− CD11b+ F4/80+) are shown. TBI macrophages were sorted to high purity and processed for
single-cell RNA sequencing. b Transcriptomes of 45 individual TBI brain macrophages were analyzed for cell lineage marker expression. Each diamond
symbol in the stacked dot plot represents a single TBI macrophage. For each cell, gene expression of markers of neurons, astrocytes, microglia, monocytes,
dendritic cells, NK cells, T and B cells, and neutrophils (N) is shown as transcripts per million (TPM). The percentage of TBI brain macrophages positively
expressing a gene (TPM> 0.1) is reported above each column
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oncogene, tyrosine kinase (Mertk) (Fig. 1b). These static
measurements exhibited variation in mRNA levels over 4
to 5 orders of magnitude but included genes whose pro-
tein products were used in our flow cytometry gating
strategy, such as Adgre1 (F4/80) and Itgam (CD11b), in
which cases the protein level was relatively uniform as mea-
sured by flow cytometry (<1 order of magnitude; Fig. 1a).
Additional myeloid-associated markers were expressed in
all, or most of these cells included integrin, alpha M (Itgam;
CD11b), and C-X3-C chemokine receptor 1 (Cx3cr1). The
lack of detected expression for any of the principal mono-
cyte markers was not related to sequence undersampling,
as cells with zero expression of a given marker were not
associated with low read coverage (Additional file 2: Figure
S2). Two markers commonly associated with both microglia
and infiltrating macrophages—Aif1 (Iba1) and Sparc—were
detectably expressed on all of the cells and about half of the
cells, respectively (Fig. 1b). Although microglia are often
indistinguishable from macrophages based on expres-
sion of commonly used markers, all cells analyzed
expressed high levels of Ccr2 transcript, which is not
expressed by microglia [22]. Furthermore, by flow
cytometry, the microglia as a bulk population were
distinguishable by their lower levels of CD45 expres-
sion (Fig. 5c). The vast majority of the cells expressed
undetectable levels of genes that are markers for
neurons, astrocytes, and other leukocyte lineages in-
cluding dendritic cells, NK cells, T cells, B cells, and
neutrophils (Fig. 1b).
TBI macrophages express mixed polarization signatures
Of the 38,126 annotated genes, 6150 genes (16.1 % of all
genes) were detectably expressed (TPM> 0.1 in >50 % of
cells). Hierarchical clustering has been used to identify
population structure within heterogeneous tissues [23–25];
similar analysis of the whole macrophage transcriptomes
did not identify any apparent subsets. For example, dimen-
sionality reduction using principal component analysis
(PCA) did not identify sub-groups of macrophages when
applied to the whole transcriptome or when applied to the
top 10 % of genes exhibiting the most variance across indi-
vidual cells (Additional file 3: Figure S3). This may be due,
at least in part, to our profiling of a comparatively homoge-
neous subset. Thus, we focused our subsequent analysis on
74 genes that have been verified as markers of mouse
macrophage subsets and polarization [12, 13, 26–28], in-
cluding a set of 26 genes proposed as a consensus of
markers of M(IL4), M(LPS, IFNγ), M(IL10), and M(IC)
polarization (Fig. 2) [11].
Overall, numerous genes representing M(IL4), M(LPS,
IFNγ), and M(IL10) groups were moderately to highly
expressed in all or many TBI macrophages, and one
gene representing the M(IC) group was highly expressed
by all cells (Fig. 2). We observed a wide range in the
magnitude of M(IL4) marker expression, with particularly
high levels of Arg1 in all cells; the large majority of the cells
(93 %) expressed Arg1 at high levels (TPM ≥ 10). There
were modest levels of the alternative activation marker
chitinase 3-like 3 (Chi3l3) mRNA in all cells. Mannose re-
ceptor, C-type lectin 1 (Mrc1), and suppressor of cytokine
signaling-2 (Socs2) were each expressed by ~70 % of the
cells, but they were not always expressed by the same cell
as less than half of the cells co-expressed both markers
(TPM> 0.1) (Fig. 4a). Less well-described M(IL4) markers
in mice, transglutaminase 2 (Tgm2) and interleukin 1 re-
ceptor antagonist (Il1rn), both of which are noted to be
M(IL4) markers in humans [11, 26, 28], were expressed by
all or nearly all cells (Fig. 2). Macrophage scavenger recep-
tor 1 (Msr1) was also expressed by all cells (Fig. 2).
With regard to M(LPS, IFNγ) genes, interleukin 1 beta
(Il1b) was detectably expressed in 91 % of the cells
(TPM> 0.1), some of which exhibited high levels of ex-
pression (29 % with TPM> 10) (Fig. 2). Similar observa-
tions were made for Tnf (91 % cells with TPM> 0.1, 38 %
with TPM> 10) (Fig. 2). Over 90 % of cells highly
expressed one or more markers of M(LPS, IFNγ)
polarization, such as interferon regulatory factor 5 (Irf5)
or nuclear factor of kappa light polypeptide gene enhancer
in B cell inhibitor, zeta (Nfkbiz) (Fig. 2). Several genes as-
sociated with antigen presentation, complement, and
chemotaxis were also expressed by all or many TBI
macrophages, including Cd86; complement component
1, q subcomponent, beta polypeptide (C1qb); comple-
ment component 3a receptor 1 (C3ar1); complement
component 5a receptor 1 (C5ar1); C-C chemokine lig-
and 2 (Ccl2); Ccl3; Ccl4; and Cxcl16 (Fig. 2). Although
they are not markers of macrophage polarization, other
chemotaxis molecules, Ccl6, Ccl7, Ccl12, Cxcl2, Cxcr2,
Ccr1, Ccr2, Ccr5, and Cxcr4, were highly expressed by
nearly all cells (Additional file 4: Figure S4). Multiple
major histocompatibility class II (MHCII) genes were
expressed on the majority of cells (H2-Aa, H2-DMa,
H2-DMb2, H2-Eb1) or all cells (H2-Ab1) (Fig. 2), al-
though MHCII molecules characterizes both M(IL4)
and M(LPS, IFNγ) cells [12, 26].
Four M(IL10) markers—interleukin 4 receptor, alpha
(Il4ra); nuclear factor, interleukin 3, regulated (Nfil3);
strawberry notch homologue 2 (Sbno2); and suppressor
of cytokine signaling 3 (Socs3)—were expressed by TBI
macrophages at frequencies of 91, 82, 69, and 47 %, re-
spectively. M(IL10)-associated Fc receptors for IgG, Fcgr1
(CD64), Fcgr2b (CD32), and Fcgr3 (CD16) were expressed
on all cells (Fig. 2), although Fcgr1 has also been suggested
to be a marker of monocyte ontogeny [29], in addition to
polarization [12, 26]. The data also revealed minimal ex-
pression of signatures associated with M(IC) polarization,
with the exception that all the cells expressed Cxcl3 [26]
(Fig. 2). Thus, the macrophage response to TBI is highly
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heterogeneous, with broad expression of markers from
each polarization class, and certain markers from each
class were expressed by all cells.
PCA was used to determine relationships and pat-
terns among the 74 polarization markers. However,
the macrophage polarization genes were not coher-
ently expressed as their relationships of expression
were no more related than data in which the order of
expression values were randomized (Fig. 3).
Complexity and incoherence in polarization signature
gene expression
In order to more closely examine whether individual
TBI macrophages exhibited signatures of distinct states
of polarization, we more closely assessed co-expression
of broadly accepted markers of mouse macrophage
polarization [11]. Correlation between gene expression
within the same polarization group was assessed by lin-
ear regression (Fig. 4a). As described above, every cell
expressed Arg1 and Chi3l3 at moderate to high levels,
but there was no correlation of the expression level of
the two genes (r2 = 0.0005) (Fig. 4a). The expression of
Arg1 and Mrc1 was also unrelated (r2 = 0.004) (Fig. 4a).
The correlation between genes of the M(IL10) group,
Sbno2:Socs3 and Nfil3:Il4ra, were similarly poor (Fig. 4a).
Gene pairs of the M(LPS, IFNγ) group, Il1b:Tnf and
Fig. 3 PCA of macrophage polarization gene expression is
compared to PCA of randomized genes. PCA of 74 markers of
macrophage polarization (left) and PCA of the same expression
data in randomized order (right) are shown for comparison
Fig. 2 TBI brain macrophages express several signature genes of M(IL4), M(IL10), and M(LPS, IFNγ) macrophage classes. Gene expression of 74
macrophage polarization genes representing distinct macrophage classes of M(IL4), M(LPS, IFNγ), M(IL10), and M(IC) were analyzed in individual
TBI macrophages by single-cell RNA sequencing. Each diamond symbol in the stacked dot plot represents a single TBI macrophage, 45 individual
cells were analyzed. The percentage of TBI brain macrophages positively expressing a gene (TPM > 0.1) is reported above each gene column
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Fig. 4 (See legend on next page.)
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Irf5:Nfkbiz, had low coefficients of determination of
0.013 and 0.001, respectively.
Expression of polarization markers across groups also
lacked collinearity. Notably, all of the cells expressing
Tnf by RNAseq also expressed both Arg1 and Chi3l3,
with no apparent relationship between the expression of
Tnf with either alternative activation marker (Fig. 4b,
Tnf:Arg1 r2 = 0.001, Tnf:Chi3l3 r2 = 0.176). Il1b expression
exhibited similar characteristics with no correlation with ei-
ther M(IL4) markers (Il1b:Arg1 r2 = 0.001, Il1b:Chi3l3 r2 =
0.019) (Fig. 4b). We also compared M(LPS, IFNγ) markers
with expression of a less strongly expressed alternative acti-
vation marker, Mrc1, which we hypothesized might reveal
more underlying structure. This was not the case; Mrc1
subsets were no less likely to express Il1b or Tnf (Fig. 4b,
Tnf:Mrc1 r2 = 0.002, Il1b:Mrc1 r2 = 0.002). Analysis of
co-expression of M(LPS, IFNγ) genes vs M(IL10) genes,
such as Irf5:Il4ra, Tnf:Sbno2, and Nfkbiz:Il4ra, also
showed no relationship (r2 = 0.008–0.042) (Fig. 4b). Fi-
nally, M(IL10) vs M(IL4) gene expression pairs, including
Nfil3:Arg1, Il4ra:Arg1, and Il4ra:Mrc1, lacked correlation
(r2 = 0.001–0.011) (Fig. 4b).
To further determine if TBI macrophages exhibit co-
herent expression of polarization markers, we analyzed
whether expression of widely used polarization markers
of classical or alternative activation could predict expression
or repression of other polarization markers. For each gene,
cells were divided into either cells expressing the gene
(TPM> 1) or cells not expressing the gene (TPM= 0.01).
Mrc1+ TBI macrophages expressed comparable levels of
Il1b and Tnf as compared to Mrc1− cells (Fig. 4c); similarly,
Socs2+ TBI macrophages had similar mean levels of co-
expression of Il1b, Tnf, Arg1, and Chi3l3 when compared
to Socs2− cells (Fig. 4c). In conclusion, we did not observe
coherence in the expression of key polarization markers
with one another, even within the same polarization class.
TBI macrophages co-express in vitro-defined polarization
markers in complex combinations
It has been shown in vitro that polarization to one acti-
vation program inhibits the gene expression of other
polarization programs [10]. In the above analysis of gene
co-expression, we found that a number of individual
macrophages co-expressed the highest expression levels
of signature genes representing distinct classes in seem-
ingly incompatible combinations. For example, the TBI
macrophages that expressed the highest levels of Arg1
(TPM > 100) were also among the cells that expressed
the highest levels of Tnf or Il1b (TPM > 100) (Fig. 4b).
Similarly, among the cells that expressed the highest levels
of Arg1 (TPM> 100) were cells that expressed the highest
levels of M(IL10) signature genes Nfil3 or Il4ra (TPM >
100) (Fig. 4b). The cells that expressed the highest levels
of M(LPS, IFNγ) markers, such as Irf5 or Nfkbiz, often
expressed the highest levels of Il4ra (Fig. 4b).
Moreover, we consistently observed that individual TBI
macrophages commonly exhibited simultaneous and strong
co-expression genes generally found to be inversely
expressed in vitro (Fig. 4b). For example, we observed high
frequencies of Arg1hi Tnfhi cells, Chi3l3hi Ilbhi cells, Il4rahi
Nfkbizhi cells, and Arg1hi Il4rahi cells, among others. The
percentage of cells with very high co-expression (TPM>
100) of at least two genes, each from a distinct polarization
group, was ~55 % (25/45 cells). Eleven percent of cells (5/
45) showed high co-expression of at least three genes
(TPM> 100), each one from a different polarization group,
such as Arg1hi Tnfhi Nfil3hi and Arg1hi Irf5hi Nfkbizhi Il4rahi
cells. Thus, not only can individual macrophages adopt a
state representing multiple distinct activation programs,
but they can do so in a variety of combinations that cross
the boundaries of in vitro polarization states.
Validation of mixed TBI macrophage activation programs
by RNA flow cytometry
To corroborate the RNAseq finding that individual mac-
rophages co-express high levels of signature polarization
genes across polarization classes, we used RNA flow cy-
tometry. First, probe specificity was confirmed using
BMDM polarized in vitro. Permeabilized BMDM were
gated for their expression of Itgam (CD11b) and Actb
(β-actin) RNA (Fig. 5a). Positive expression was deter-
mined by comparison with a non-specific RNA probe,
DapB. In LPS-stimulated BMDM, RNA probes detected
expression of Tnf and Il1b, with no detection of Arg1 or
Mrc1 above unstimulated controls (Fig. 5b). In IL4-
stimulated BMDM, RNA flow cytometry detected Arg1
and Mrc1 expression, with no upregulation of M(LPS,
IFNγ) markers (Fig. 5b).
(See figure on previous page.)
Fig. 4 Co-expression analysis of macrophage polarization markers demonstrate incoherent expression in TBI macrophages. a Pairwise dot plots of
absolute expression values of widely accepted signature macrophage polarization markers in TBI macrophages are shown. Co-expression analyses
of signature genes within the same group were analyzed by linear regression analysis, and Pearson’s correlation coefficients (r2) and the lines of
best fit are presented. b Pairwise dot plot of absolute expression values of signature macrophage polarization markers across classes were analyzed in
TBI macrophages. Results of linear regression analysis and r2 are shown. c Signature macrophage polarization markers were analyzed for their capacity
to predict gene expression of other signature macrophage polarization markers and shown here in stacked dot plots. The capacity of Mrc1 (TPM> 1)
or lack of Mrc1 (TPM= 0.01) in a TBI macrophage to predict the mean expression level of Il1b or Tnf was statistically analyzed by Mann-Whitney U tests.
All p values were insignificant (p < 0.05). Similarly, the expression of or lack of expression of Socs2 in a TBI macrophage failed to predict the mean
expression level of Tnf, Arg1, and Chi3l3
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We next performed RNA flow cytometry on TBI brain
leukocytes, as well as on sham-injured brain leukocytes,
isolated from the ipsilateral hemisphere 1 day after sur-
gery (Fig. 5c, d). TBI macrophages exhibited upregula-
tion of Tnf, Il1b, Arg1, Mrc1, and Chi3l3, compared to
macrophages from sham-injured brains (Fig. 5d). Com-
pared to RNAseq, the overall sensitivity of RNA flow
cytometry was lower, as expected. As observed by RNA-
seq, RNA flow identified macrophage subsets exhibiting
high expression of Tnf in conjunction with M(IL4) gene
expression (i.e., Arg1, Mrc1, or Chi3l3) (Fig. 6). Similar ob-
servations were made for Il1b and its co-expression with
Arg1, Mrc1, or Chi3l3 (Fig. 6). These data corroborated
the existence of macrophages co-expressing M(LPS, IFNγ)
genes with M(IL4) genes at the highest levels.
Discussion
We previously reported mixtures of signature polarization
genes in macrophages responding to experimental TBI
[6]. To elucidate whether the mixed polarization of
Fig. 5 Signature polarization genes are upregulated in brain macrophages post-TBI. a RNA flow cytometry was performed on bone marrow-derived
macrophages (BMDM) that were gated for surface Itgam (CD11b) expression and intracellular Actb RNA expression. The latter is a gate for permeabilized
cells. b RNA flow cytometry was performed on unstimulated (gray), LPS-polarized (red), and IL4-polarized (blue) BMDM. Probes for RNA expression of M(LPS,
IFNγ) markers, Tnf and Il1b, and M(IL4) markers, Arg1 and Mrc1 were used to stain permeabilized BMDM and analyzed by flow cytometry. N= 3 independent
experiments. c Ipsilateral hemisphere brain leukocytes were harvested from mice 1 day after TBI or sham surgery. Flow cytometry plots represent the gates
used for live macrophages. d Macrophages harvested from ipsilateral brain hemispheres of mice 1 day after TBI (left, n= 6 independent experiments) and
sham surgery (right, n= 3 independent experiments) were assessed by RNA flow cytometry. Analysis markers were drawn based on non-specific
background staining using DapB RNA probes for a bacterial gene. The percentage of positive expression shown is the difference in the
percent of brain macrophages expressing the M1 or M2 gene and the percent of cells with background detection of DapB RNA
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macrophages detected in TBI was due to the presence of a
mixture of polarized subsets and/or whether novel states
of macrophage activation existed, we employed two
powerful assays for elucidating transcript levels at the
resolution of single cells: single-cell RNAseq and RNA
flow cytometry. Using these approaches, we showed that
TBI macrophages not only express several signature genes
of distinct polarization states (i.e., M(IL4), M(LPS, IFNγ)
and M(IL10)) but that signatures from distinct states are
often expressed in combination with one another simul-
taneously in a single cell. Although demonstrating the
functional relevance of these states will require further
study, protein analysis by histology reported by others
showed expression of Il1b and tumor necrosis factor
(TNF) segregated and colocalized in macrophages in
ischemic brain injury [30]; in TBI, histological protein
analysis revealed Arg1+iNOS+ microglia/macrophages in
the brain tissue [4] as well as CD36 and MARCO co-
expression on microglia/macrophages [18]. Future efforts
should more deeply profile protein expression with a
larger number of parameters and use perturbational
approaches to determine the associated cellular functions
of these understudied leukocyte subsets. Our data extend
earlier work to demonstrate that TBI macrophages exhibit
expression of signature genes from two or more
polarization states in a broad range of unexpected gene
combinations. Further, these findings provide evidence
that the mixed macrophage response to TBI is an unusual
activation state rather than admixture of differentially po-
larized macrophages. Importantly, our data highlight the
complex nature of macrophage activation in vivo that is
inadequately described by current nomenclature based on
in vitro studies.
In fact, we did not detect any TBI macrophages that
were distinctly polarized to a single state; all macrophages
exhibited expression of markers associated with two or
more known polarization states. Given that macrophages
are known to have some limited plasticity to transition
from one polarization state to another, we considered that
TBI macrophages could be expressing mixed polarization
markers due to being in a state of transition. Although
we cannot completely rule out the possibility that TBI
macrophages at this time point are transitioning to dis-
tinct polarization states, one would expect an assay of
single cells to reveal a distribution of cells more
strongly polarized to one or another state, with lower
mean levels of gene expression of the associated genes
during the transition. We did not observe this to be the
case; many cells with the highest expression levels of a
signature of one polarization state also exhibited the high-
est expression levels for a distinct polarization state. The
determination of gene expression profiles at downstream
time points is needed to better elucidate the full repertoire
and dynamics of macrophage activation states over the
Fig. 6 RNA flow cytometry validates that TBI macrophages co-express macrophage polarization markers across classes in unusual combinations.
RNA flow cytometry for M(LPS, IFNγ) markers, Tnf and Il1b, were analyzed for their co-expression with M(IL4) markers, Arg1, Mrc1, and Chi3l3, in
ipsilateral TBI brain hemispheres 1 day post-TBI. Quadrant gates were drawn based on DapB RNA probe binding. N = 3 independent experiments,
with pooled tissues of eight age-matched cage mate mice for each experiment
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course of TBI. Further studies to investigate and compare
the pathways of activation for the tissue-resident macro-
phages in the brain, the microglia, may shed light on how
cellular origin affects function and how to more precisely
target therapeutics.
The above findings have important clinical implications.
Several chemotaxis and complement-associated genes
were expressed by all TBI macrophages, including Ccr2.
These may be potential therapeutic targets or biomarkers.
In fact, studies have identified Ccr2 as a potential target to
improve the functional outcomes of TBI [5, 7, 21, 31].
Taken together, these data suggest that individual Ccr2-
dependent TBI macrophages are activated to become
multi-dimensional, but that their net influence is debilitat-
ing. Most notably, our findings indicate that the same
macrophages responsible for pathological neuroinflamma-
tion also express genes that promote immunoregulation
and wound healing. By extension, it may be beneficial to
focus therapeutic efforts on modulating myeloid cell acti-
vation rather than depleting these cells or completely
blocking their infiltration. However, our studies show that
efforts to shape TBI macrophages must address the chal-
lenge that the target cells are already broadly activated.
Conclusions
Traumatic brain injury (TBI) is a major public health
problem with no known effective pharmacological ther-
apy. Primary goals of therapy are to preserve brain tissue
and to promote wound healing, which might be possible
through modulation of the neuroinflammatory response.
Using single-cell gene expression methods, we show that
monocyte-derived macrophages, a major population of in-
nate immune cells responding to acute TBI, are not com-
prised of distinctly polarized pro-inflammatory or pro-
reparative subsets. Instead, there is a deep complexity to
acute TBI macrophage activation in vivo, with cells adopt-
ing unique activation states and concurrently adopting
features associated with both inflammation and wound
healing, thus shifting the paradigm of in vivo macrophage
polarization. These data reveal important considerations
for therapeutic approaches that aim to alter inflammation
in vivo and shape macrophage activation.
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